Literature DB >> 137922

A comparison of the bronchodilator activity of Sch 1000 and salbutamol.

R E Ruffin, J D Fitzgerald, A S Rebuck.   

Abstract

The effects of the beta 2-adrenergic agonist, salbutamol, 200 mug, and the cholinergic antagonist, Sch 1000, 40 mug, have been compared in 25 asthmatic patients using a single dose, double-blind, crossover trial design. Salbutamol aerosol produces a greater degree of bronchodilatation than Sch 1000 aerosol during the initial three hours following drug administration. There is no significant difference in the bronchodilator effects of the two drugs in the interval four to eight hours after drug administration. Nonatopic patients showed less difference in bronchodilator response to each of the two drugs than atopic patients. Neither drug showed any significant adverse effect on blood pressure, pulse rate, or electrocardiogram. In six asthmatic patients the effect of the combination of salbutamol, 200 mug, and Sch 1000, 40 mug, was evaluated. The combination produced a longer duration of bronchodilatation than either drug alone when compared to placebo.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 137922     DOI: 10.1016/0091-6749(77)90215-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  15 in total

1.  Ipratropium bromide (Sch 1000) monohydrate aerosol: bronchodilator effect of three dose levels in asthmatics.

Authors:  R E Ruffin; M T Newhouse
Journal:  Lung       Date:  1978       Impact factor: 2.584

Review 2.  Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.

Authors:  Bart C Moulton; Allison D Fryer
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Dose response of ipratropium assessed by two methods.

Authors:  C J Allen; A H Campbell
Journal:  Thorax       Date:  1980-02       Impact factor: 9.139

Review 4.  Combination bronchodilator therapy.

Authors:  G M Shenfield
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

5.  A comparative study of atropine methonitrate, salbutamol, and their combination in airways obstruction.

Authors:  R J Pierce; C J Allen; A H Campbell
Journal:  Thorax       Date:  1979-02       Impact factor: 9.139

6.  Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation.

Authors:  I G Brown; C S Chan; C A Kelly; A G Dent; P V Zimmerman
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

7.  Nebulized salbutamol vs salbutamol and ipratropium combination in asthma.

Authors:  Anita Sharma; Arvind Madaan
Journal:  Indian J Pediatr       Date:  2004-02       Impact factor: 1.967

Review 8.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 9.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

10.  A single dose comparison of a combination of fenoterol and ipratropium aerosols in bronchial asthma.

Authors:  P Lawford; K N Palmer
Journal:  Postgrad Med J       Date:  1983-01       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.